MBA, PhD MAICD
Ian Dixon is a seasoned biotechnology entrepreneur with more than 20 years’ experience in the Australian sector. Together with Graham Kelly, he founded Nyrada Inc. Ian is a co-inventor of the technology behind its Cholesterol Lowering Program, giving him deep expertise in the development of PCSK9 inhibitors. Ian is also Chairman and founder of Altnia Group, a privately held Australian biotechnology incubator and life sciences R&D company.
Currently Founder and Managing Director of exosome medicine company, Exopharm (ASX: EX1), Ian also serves as a part-time executive director of Medigard Ltd (ASX: MGZ). In addition, Ian co-founded Cynata Inc. – now a subsidiary of Australian listed biotechnology company, Cynata Therapeutics Ltd (ASX: CYP). Until recently he was a non-executive director of Noxopharm Ltd (ASX: NOX), Nyrada’s largest shareholder.
Ian has a PhD in biomedical engineering from Monash University, an MBA from Swinburne University and professional engineering qualifications.